Breakthroughs in Phelan-McDermid Syndrome Treatment and Adbris Acquisition Proposal

Key Points:

Syndrome Trial:

• • The NNZ-2591 Phase 2 trial demonstrates significant improvements in PMS.
  • Clinician and caregiver assessments highlight positive changes in communication, behavior, cognition, and socialization.
  • Preliminary Feasibility Study (PFS) results anticipated by the end of 2023.

Acquisition Proposal:

• • CRH and Barro Group propose a AU$3.20 cash per share offer, a 41% premium.
  • Process and exclusivity deed signed, subject to FIRB approval and other conditions.
  • Proposal implies an equity valuation of approximately AU$2.1 billion for Adbri.

Positive Results in NNZ-2591 Phase 2 Trial for Phelan-McDermid Syndrome

Neuren Pharmaceuticals (ASX: NEU) has unveiled promising outcomes from its Phase 2 clinical trial of NNZ-2591, showcasing significant improvements in children with Phelan-McDermid syndrome (PMS). Clinicians and caregivers observed notable enhancements across communication, behavior, cognition, and socialization. Preliminary Feasibility Study (PFS) results are expected by the end of 2023, indicating a potential breakthrough in addressing the severe impact of PMS.

Adbri Attracts Acquisition Interest with a 41% Premium Offer

Adbri Limited (ASX: ABC) has received a non-binding indicative proposal from CRH and the Barro Group at a cash offer of AU$3.20 per share, reflecting a substantial 41% premium to the last close. The proposal, subject to various conditions, including FIRB approval, values Adbri at approximately AU$2.1 billion. If finalized, this acquisition could reshape the landscape of the construction materials sector, with Adbri's independent board committee intending to recommend the proposal, pending no superior offers.

Closing Note:

These developments underscore advancements in medical research and corporate strategies, with potential implications for healthcare and construction material sectors. Investors and stakeholders will closely monitor the progression of NNZ-2591 in addressing Phelan-McDermid syndrome and the unfolding dynamics of Adbri's proposed acquisition.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com